Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors

Abstract

Pancreatic neuroendocrine tumors (PNET) may develop sporadically or in the context of hereditary syndromes. In patients with multiple endocrine neoplasia type 1 (MEN1), PNET is the leading cause of death. Our aim was to compare the mortality risk in sporadic and MEN1-related PNETs and identify high-risk populations. A retrospective Surveillance, Epidemiology, and End Results database analysis of patients with PNET was used. Patients with MEN1 were defined by syn/metachronous pituitary adenoma. Clinical data were retrieved, and all-cause mortality (ACM) risk was compared in univariate and multivariable analyses. The cohort included 569 patients (46.6% males) with sporadic (n=542) and MEN1-related (n=27) PNETs. Age at diagnosis of MEN1-related PNET was significantly younger than with sporadic PNETs (mean age 49.2±16.7 vs. 61.6±12.7 years, respectively; p < 0.001). Survival analysis showed a trend for a better outcome in patients with MEN1-related vs. sporadic PNET (Log-rank, p=0.09) and in subgroup analysis for patients with advanced disease (p=0.08). Furthermore, among patients followed expectantly, those with MEN1-related PNET had lower ACM risk than their sporadic counterparts (p=0.08). Multivariable analysis demonstrated lower ACM risk in patients diagnosed with MEN1 (hazard ratio 0.35, 95% confidence interval 0.11–1.2, p=0.09), further supporting the trend detected in the univariate analysis. In conclusion, our study demonstrates the distinct clinical profile of patients with MEN1-related PNET compared to sporadic disease and emphasizes the expertise required to accurately manage patients with PNET in this rare context. The cautious decision-making required before embarking on surgical intervention is further emphasized in this robust analysis of a large cancer database.

Key words

MEN1 - mortality - pancreas - neuroendocrine tumors

Publikationsverlauf

Eingereicht: 24. Januar 2021

Angenommen nach Revision: 17. März 2021

Artikel online veröffentlicht:
20. April 2021

• References

• 1 Norton JA, Krampitz G, Jensen RT. Multiple Endocrine Neoplasia: Genetics and Clinical Management. Surg Oncol Clin N Am 2015; 24: 795-832
• 2 Jensen RT, Norton JA. Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia-Type 1(MEN1): Some Clarity but Continued Controversy. Pancreas 2017; 123: 4757-4763
• 3 Thakker RV, Newey PJ, Walls GV. et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011
• 4 Eller-Vainicher C, Chiodini I, Battista C. et al. Sporadic and MEN1-related primary hyperparathyroidism: Differences in clinical expression and severity. J Bone Miner Res 2009; 24: 1404-1410
• 5 Brandi ML, Gagel RF, Angeli A. et al. CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 2001; 86: 5658-5671
• 6 Carty SE, Helm AK, Amico JA. et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998; 124: 1106-1114
• 7 Jensen RT, Berna MJ, Bingham DB. et al. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 2008; 113: 1807-1843
• 8 Brandi ML, Bordi C, Tonelli F. et al. Multiple Endocrine Neoplasia Type 1. Princ Bone Biol Two-Volume Set 2008; 2: 1345-1374
• 9 Van Leeuwaarde RS, Dreijerink KM, Ausems MG. et al. MEN1-dependent breast cancer: Indication for early screening? Results from the Dutch MEN1 study group. J Clin Endocrinol Metab 2017; 102: 2083-2090
• 10 Ito T, Igarashi H, Uehara H. et al. Causes of Death and Prognostic Factors in Multiple Endocrine Neoplasia Type 1. Medicine (Baltimore) 2013; 92: 135-181
• 11 Dean PG, Van Heerden JA, Farley DR. et al. Are patients with multiple endocrine neoplasia type I prone to premature death?. World J Surg 2000; 24: 1437-1441
• 12 Geerdink EAM, Van der Luijt RB, Lips CJM. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening?. Eur J Endocrinol 2003; 149: 577-582
• 13 World Health Organization. International Classification of Diseases for Oncology. Third Edition First Revision. 2013
• 14 Amin MB, Edge SB. American Joint Committee on Cancer. AJCC Cancer Staging Manual. In Internet http://www.springer.com/us/book/9783319406176 Stand: 06.11.2017
• 15 Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumours in patients with MEN1. Lancet Diabetes Endocrinol 2015; 3: 895-905
• 16 Chiloiro S, Lanza F, Bianchi A. et al. Pancreatic neuroendocrine tumors in MEN1 disease: A mono-centric longitudinal and prognostic study. Endocrine 2018; 60: 362-367
• 17 Artic L, Pieterman CRC, De Laat JMDe. et al. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1. Results From the Dutch MEN1 Study Group 2017; 102: 3795-3805
• 18 Triponez F, Goudet P, Dosseh D. et al. Is surgery beneficial for MEN1 patients with small (≤2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654-662
• 19 de Laat JM, van der Luijt RB, Pieterman CRC. et al. MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. BMC Med 2016; 14: 1-9